Gossamer Bio, Inc. (GOSS)
Nasdaq · Healthcare · Biotechnology
$10.65−0.56%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $65.1M
- 52-week range
- $9.12 – $309.60
- 52-week change
- −94.45%
- EPS (trailing)
- −$52.80
- Analyst rating
- 2.4 Buy
- Next earnings
- Nov 4, 2026
Fiscal year to Dec 2025
- Revenue
- $48.5M (−57.74%)
- Net income
- −$170M
- Operating margin
- −352.2%
- Diluted EPS
- −$0.75
- Free cash flow
- −$171M
From the company’s annual report on SEC EDGAR.
About Gossamer Bio, Inc.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Headquarters: San Diego, United States · 161 employees · gossamerbio.com